Selank vs NNZ-2591
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Selanc, TP-7
Selank is a synthetic seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) built from the natural immune peptide tuftsin, with a small chemical tweak to make it last longer in the body. It was developed in Russia as an anti-anxiety and nootropic agent and is approved there for generalized anxiety disorder, but it has no FDA or EMA approval and almost no Western clinical data. The pitch is calm and focus without the sedation, dependence, or withdrawal that come with benzodiazepines.
Also: Cyclo-L-glycyl-L-2-allylproline, Cyclic glycine-proline analog
NNZ-2591 is Neuren Pharmaceuticals' second drug, a synthetic analog of cyclic glycine-proline (cGP), a small ring-shaped molecule the body makes when it breaks down IGF-1. It is taken by mouth and is being developed for rare childhood neurodevelopmental disorders: Phelan-McDermid syndrome is furthest along, with the first-ever phase 3 trial in that disease started in late 2025, and Angelman and Pitt Hopkins syndromes behind it. Phase 2 results looked encouraging, but they were small open-label studies, so nobody knows yet whether it truly works.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Selank | NNZ-2591 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Selank seems to work through several overlapping systems rather than one tidy target. It influences GABA signaling, the brain's main calming neurotransmitter system, which likely accounts for its anti-anxiety effect. It also slows the breakdown of enkephalins, the body's own opioid-like peptides involved in mood and stress, which is a mechanism entirely different from benzodiazepines or SSRIs. Animal work additionally points to effects on serotonin and dopamine balance and on BDNF, a growth factor tied to learning and neuron health. These pathways are well documented in rodents; the picture in humans is inferred rather than directly measured. | Cyclic glycine-proline is thought to fine-tune IGF-1 activity in the brain by changing how IGF-1 binds to its carrier protein IGFBP-3. A 2014 Scientific Reports study proposed that cGP nudges IGF-1 activity up when it is low and down when it is high, a normalizing effect rather than a simple boost. NNZ-2591 adds an allyl group to the proline ring, making it resistant to enzymes and able to reach the brain after oral dosing. Trial protocols also describe reduced neuroinflammation and support for synapse function in animal models. It is a close cousin of trofinetide in spirit (both are small IGF-1-derived molecules from the same company), but the exact way it helps in these genetic syndromes has not been pinned down in humans. |
| Common Dosing | 250-500 mcg 2-3x daily 2-3x daily | 12 mg/kg twice daily (phase 2 target trial dose) Twice daily |
| Administration | Intranasal spray (most common), subcutaneous injection | Oral liquid |
| Typical Duration | 14-21 days typical | 13 weeks in phase 2 and phase 3 trials, with 12-month open-label extensions |
| Best Time to Take | Morning or as needed for anxiety | Twice daily (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Most of the rigorous data is preclinical and Russian. In rodents, Selank shows consistent anxiety-reducing and mild cognitive effects, and one PMC-indexed study found it enhanced diazepam's anti-anxiety effect under chronic stress. The main human clinical reference is a Russian comparative trial by Zozulia, Neznamov, and colleagues in patients with generalized anxiety disorder and neurasthenia, reporting that Selank's anxiolytic effect was comparable to the benzodiazepine medazepam on standard rating scales, with added anti-fatigue benefits and changes in enkephalin activity. The honest caveat: that trial was relatively small, the published English abstract gives qualitative results rather than hard effect sizes and p-values, and it has not been replicated by independent Western groups. So the evidence supports a real but modestly studied anxiolytic, mostly validated within the regulatory system that approved it. | The human data so far come from three small, open-label phase 2 trials of 13 weeks each, all with twice-daily oral dosing titrated up to a target of 12 mg/kg. In Phelan-McDermid syndrome (18 children, published in Neurology Genetics in 2026), 10 of 14 efficacy measures improved significantly from baseline, including clinician and caregiver global ratings, behavior, sleep and communication, and the drug was well tolerated with mostly mild to moderate side effects. Angelman syndrome (reported August 2024) showed a mean CGI-I of 3.0, with 11 of 13 children rated improved by clinicians. Pitt Hopkins syndrome (reported May 2024) showed improvement in 6 of 11 children on clinician-rated severity. The big caveat: none of these had a placebo group, and rare-disease trials with caregiver-rated outcomes are especially prone to placebo effects. A planned Prader-Willi trial was withdrawn before enrolling anyone. The real test is Koala, a randomized, double-blind, placebo-controlled phase 3 trial in about 160 children aged 3 to 12 with Phelan-McDermid syndrome (first patient dosed February 2026; estimated primary completion late 2027), with an open-label extension started in 2026. The FDA has given the program Fast Track, Rare Pediatric Disease and Orphan Drug designations. Neuren has also started work in neonatal hypoxic-ischemic encephalopathy, which is still preclinical. |
Frequently Asked Questions: Selank vs NNZ-2591
What is the difference between Selank and NNZ-2591?
Selank is a cognitive peptide that selank is a synthetic seven-amino-acid peptide (thr-lys-pro-arg-pro-gly-pro) built from the natural immune peptide tuftsin, with a small chemical tweak to make it last longer in the body. it was developed in russia as an anti-anxiety and nootropic agent and is approved there for generalized anxiety disorder, but it has no fda or ema approval and almost no western clinical data. the pitch is calm and focus without the sedation, dependence, or withdrawal that come with benzodiazepines. NNZ-2591 is a cognitive peptide that nnz-2591 is neuren pharmaceuticals' second drug, a synthetic analog of cyclic glycine-proline (cgp), a small ring-shaped molecule the body makes when it breaks down igf-1. it is taken by mouth and is being developed for rare childhood neurodevelopmental disorders: phelan-mcdermid syndrome is furthest along, with the first-ever phase 3 trial in that disease started in late 2025, and angelman and pitt hopkins syndromes behind it. phase 2 results looked encouraging, but they were small open-label studies, so nobody knows yet whether it truly works. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Selank or NNZ-2591?
Neither is universally "better" - the choice depends on your specific goals. Selank is typically used for cognitive purposes, while NNZ-2591 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Selank and NNZ-2591 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Selank and NNZ-2591 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.